Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Expected to Post Quarterly Sales of $22.68 Million
Analysts forecast that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will post sales of $22.68 million for the current quarter, according to Zacks. Five analysts have issued estimates for Arrowhead Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $17.80 million and the highest estimate coming in at $36.00 million. Arrowhead Pharmaceuticals posted sales of $48.15 million in the same quarter last year, which suggests a negative year-over-year growth rate of 52.9%. The company is scheduled to report its next quarterly earnings results on Wednesday, May 13th.
On average, analysts expect that Arrowhead Pharmaceuticals will report full-year sales of $109.11 million for the current year, with estimates ranging from $50.00 million to $257.80 million. For the next fiscal year, analysts expect that the business will post sales of $128.73 million, with estimates ranging from $40.00 million to $231.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported ($0.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.04 by ($0.07). Arrowhead Pharmaceuticals had a return on equity of 18.21% and a net margin of 32.56%. The company had revenue of $29.46 million during the quarter, compared to analyst estimates of $36.63 million.
Shares of NASDAQ ARWR traded down $1.25 during trading on Friday, reaching $38.49. The company had a trading volume of 1,057,079 shares, compared to its average volume of 1,457,754. Arrowhead Pharmaceuticals has a twelve month low of $17.27 and a twelve month high of $73.72. The stock has a market capitalization of $4.04 billion, a PE ratio of 72.62 and a beta of 1.95. The stock has a 50-day moving average price of $48.22 and a two-hundred day moving average price of $44.22. The company has a current ratio of 6.89, a quick ratio of 6.89 and a debt-to-equity ratio of 0.03.
In other news, General Counsel Patrick O’brien sold 14,625 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $60.12, for a total value of $879,255.00. Following the completion of the sale, the general counsel now owns 267,406 shares of the company’s stock, valued at $16,076,448.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Kenneth Allen Myszkowski sold 40,313 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $49.44, for a total value of $1,993,074.72. Following the completion of the sale, the chief financial officer now directly owns 424,536 shares of the company’s stock, valued at approximately $20,989,059.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 248,518 shares of company stock valued at $15,591,357. 4.00% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its position in shares of Arrowhead Pharmaceuticals by 96.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,020 shares of the biotechnology company’s stock worth $29,000 after buying an additional 500 shares during the period. Global Retirement Partners LLC purchased a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at about $44,000. Great Diamond Partners LLC purchased a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at about $47,000. Sowell Financial Services LLC boosted its holdings in Arrowhead Pharmaceuticals by 1,650.0% in the fourth quarter. Sowell Financial Services LLC now owns 1,120 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 1,056 shares during the last quarter. Finally, First Mercantile Trust Co. purchased a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at about $101,000. 66.53% of the stock is owned by institutional investors.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.